Binding of 125I-labelled encephalitogenic basic protein to normal lymphocytes. Inhibition with multiple sclerosis serum

A sheep lymphocyte 125I-labelled human encephalitogenic basic protein (125I-BP) binding assay was used to study the correlation of 125I-BP binding with the diagnosis and status of multiple sclerosis (MS) patients. MS serum generally caused significant inhibition of binding, and serum from MS patient...

Full description

Saved in:
Bibliographic Details
Published inClinical and experimental immunology Vol. 19; no. 3; pp. 451 - 458
Main Authors McPherson, T A, Liburd, E M, Seland, T P
Format Journal Article
LanguageEnglish
Published England 01.03.1975
Subjects
Animals
Antilymphocyte Serum
Humans
Lymphocytes - immunology
Multiple Sclerosis - immunology
Myelin Basic Protein
Protein Binding
Sheep - immunology
Online AccessGet full text

Cover

More Information
Summary:A sheep lymphocyte 125I-labelled human encephalitogenic basic protein (125I-BP) binding assay was used to study the correlation of 125I-BP binding with the diagnosis and status of multiple sclerosis (MS) patients. MS serum generally caused significant inhibition of binding, and serum from MS patients in remission caused significantly more inhibition than serum from MS patients in relapse. Serum inhibition increased in association with improvement in neurological status in three out of four MS patients studied for more than 10 months.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0009-9104
1365-2249